{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:42:39Z","timestamp":1794440559282,"version":"4.9.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.annonc.2024.11.011","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T11:21:54Z","timestamp":1732879314000},"page":"321-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial"],"prefix":"10.1016","volume":"36","author":[{"given":"A.","family":"Alvarez Secord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.N.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-0347","authenticated-orcid":false,"given":"A.","family":"Barqu\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0742-2383","authenticated-orcid":false,"given":"F.","family":"G\u00e1lvez-Montosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.E.","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2472-8306","authenticated-orcid":false,"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Rubio P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Diver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-M.","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6608-2585","authenticated-orcid":false,"given":"B.R.","family":"Corr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2024.11.011_bib2","article-title":"Treatment of epithelial ovarian cancer","volume":"371","author":"Kuroki","year":"2020","journal-title":"Br Med J"},{"key":"10.1016\/j.annonc.2024.11.011_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fonc.2013.00251","article-title":"Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment","volume":"3","author":"Chien","year":"2013","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.11.011_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.03.022","article-title":"An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations","volume":"146","author":"Salani","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.11.011_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2024.11.011_bib7","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/medicina59071183","article-title":"Epithelial ovarian cancer: a five year review","volume":"59","author":"Arnaoutoglou","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.annonc.2024.11.011_bib8","first-page":"103","article-title":"Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives \u2013 a review","volume":"12","author":"Gupta","year":"2019","journal-title":"J\u00a0Ovarian Res"},{"issue":"9","key":"10.1016\/j.annonc.2024.11.011_bib9","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1002\/ijc.33395","article-title":"Multiple lines of chemotherapy for patients with high-grade ovarian cancer: predictors for response and effect on survival","volume":"148","author":"Kessous","year":"2021","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2024.11.011_bib10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12016-021-08877-y","article-title":"Hypersensitivity reactions to platinum agents and taxanes","volume":"62","author":"Tsao","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"10.1016\/j.annonc.2024.11.011_bib11","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3390\/cancers12061607","article-title":"Overcoming platinum and PARP-inhibitor resistance in ovarian cancer","volume":"12","author":"McMullen","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"suppl 3","key":"10.1016\/j.annonc.2024.11.011_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-199958003-00007","article-title":"Oral etoposide for the treatment of recurrent ovarian cancer","volume":"58","author":"Ozols","year":"1999","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.annonc.2024.11.011_bib13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2008.02.028","article-title":"Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers","volume":"109","author":"Morris","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2024.11.011_bib14","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2024.11.011_bib15","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.11.011_bib16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ygyno.2024.05.014","article-title":"Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients","volume":"187","author":"Carballo","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2024.11.011_bib17","series-title":"Ovarian Cancer","year":"2022"},{"issue":"10","key":"10.1016\/j.annonc.2024.11.011_bib18","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.11.011_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","article-title":"Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome","volume":"156","author":"Cecere","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"18","key":"10.1016\/j.annonc.2024.11.011_bib20","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3390\/cancers14184414","article-title":"Multicenter real-world data of\u00a0subsequent chemotherapy after progression to PARP inhibitors in\u00a0a maintenance relapse setting","volume":"14","author":"Romeo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2024.11.011_bib21","unstructured":"Harter P, Mouret-Reynier M-A, Lorusso D, et al. Presented at: 2023 American Society of Clinical Oncology; June 2-6, 2023; Chicago, IL. Abstract 5550."},{"issue":"1","key":"10.1016\/j.annonc.2024.11.011_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ygyno.2022.02.002","article-title":"Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1\/2-mutated epithelial ovarian cancer: a multicentre retrospective study","volume":"165","author":"Park","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2024.11.011_bib23","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/CAD.0000000000001219","article-title":"PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer","volume":"32","author":"Rose","year":"2021","journal-title":"Anticancer Drugs"},{"issue":"7","key":"10.1016\/j.annonc.2024.11.011_bib24","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-\u03b1 (FR\u03b1)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.annonc.2024.11.011_bib25","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.11.011_bib26","unstructured":"ELAHERE (mirvetuximab soravtansine-gynx) [prescribing information]. ImmunoGen, Inc.; Waltham, MA.; 2024."},{"issue":"23","key":"10.1016\/j.annonc.2024.11.011_bib27","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.annonc.2024.11.011_bib28","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.11.011_bib29","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer V.3.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2024. Available at: NCCN.org. Accessed August 1, 2024. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"13","key":"10.1016\/j.annonc.2024.11.011_bib30","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.11.011_bib31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2024.11.011_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.annonc.2024.11.011_bib33","doi-asserted-by":"crossref","unstructured":"O\u2019Malley D, Oaknin A, Matulonis U, et\u00a0al. Mirvetuximab soravtansine and bevacizumab in folate receptor alpha-positive ovarian cancer: efficacy in patients with and without prior bevacizumab [abstract]. Presented at International Gynecologic Cancer Society Annual Meeting. September 29-October 1, 2022; New York City, New York; Abstract 496.","DOI":"10.1136\/ijgc-2022-igcs.13"},{"key":"10.1016\/j.annonc.2024.11.011_bib34","series-title":"VENTANA FOLR1 (FOLR1-2.1) RxDx assay","year":"2022"},{"issue":"6","key":"10.1016\/j.annonc.2024.11.011_bib35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.annonc.2024.11.011_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"4","key":"10.1016\/j.annonc.2024.11.011_bib37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"6","key":"10.1016\/j.annonc.2024.11.011_bib38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2024.11.011_bib39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1078-0432.CCR-21-1186","article-title":"Pamiparib monotherapy for patients with germline BRCA1\/2-mutated ovarian cancer previously treated with at least two lines of chemotherapy: a multicenter, open-label, phase II study","volume":"28","author":"Wu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.annonc.2024.11.011_bib40","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/medicina59030544","article-title":"Ovarian cancer-insights into platinum resistance and overcoming it","volume":"59","author":"Havasi","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2024.11.011_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.7-suppl_5-11","article-title":"Management of treatment-related toxicity in advanced ovarian cancer","volume":"7","author":"Dunton","year":"2002","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.annonc.2024.11.011_bib43","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: a review","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.annonc.2024.11.011_bib44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2024.10.013","article-title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: an integrated safety summary","volume":"191","author":"Moore","year":"2024","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424049482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424049482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:19:44Z","timestamp":1759349984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424049482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0923753424049482"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.11.011","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}